Scientists Discover New Osteoporosis Treatment Pathway via TGF-β Signalling

Scientists at Seoul National University have uncovered a new molecular pathway that could change how osteoporosis is treated. The discovery focuses on the role of TGF-β signalling in controlling bone cell activity. Their findings suggest a potential breakthrough for safer and more effective therapies. Osteoporosis weakens bones by reducing mass and disrupting their internal structure. The condition arises when osteoclasts, which break down old bone, outpace osteoblasts, the cells responsible for forming new bone. Current treatments often target sclerostin, a protein that suppresses osteoblast activity, but new research points to an additional pathway.

A team led by Professors Sunghoon Kwon and Sang Wan Kim used advanced transcriptomic techniques to map osteoblast behaviour in detail. They found that inactive osteoblasts have a unique gene expression pattern, distinct from their active counterparts. When reactivated, these cells closely resemble fully functional osteoblasts.

The study identified TGF-β signalling as a major factor keeping osteoblasts dormant. Blocking this pathway, alongside sclerostin inhibition, produced striking results. Combined treatment boosted trabecular bone volume and thickness while reducing gaps between bone structures more effectively than single therapies. Targeting TGF-β alongside existing methods could offer a more balanced approach to bone regeneration. This dual strategy may restore skeletal health more thoroughly than current options. The findings open doors for developing treatments that are both potent and safer for long-term use.